COVID-19 and the orphan biologic polyvalent immunoglobulin – “Let food be thy medication” (Hippocrates of Kos c. 460 – c. 370 BC)

2020 ◽  
Vol 58 (12) ◽  
pp. 675-677
Author(s):  
Barry G. Woodcock
Keyword(s):  
Polyvalent Immunoglobulin

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain–Barre syndrome

2003 ◽  
Vol 28 (2) ◽  
pp. 117-124 ◽  
Author(s):  
P. Chamouni ◽  
F. Tamion ◽  
I. Gueit ◽  
C. Girault ◽  
P. Lenain ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Polyvalent Immunoglobulin

scholarly journals In vitro effects of polyvalent immunoglobulin for intravenous use.

1994 ◽  
Vol 57 (Suppl) ◽  
pp. 15-17 ◽  
Author(s):  
I N van Schaik ◽  
M Vermeulen ◽  
A Brand
Keyword(s):  
In Vitro Effects ◽  
Polyvalent Immunoglobulin

Polyvalent immunoglobulin preparations inhibit pneumolysin-induced platelet destruction

2021 ◽  
Author(s):  
Friederike Wiebe ◽  
Stefan Handtke ◽  
Jan Wesche ◽  
Annabel Schnarre ◽  
Raghavendra Palankar ◽  
...  
Keyword(s):  
Respiratory Distress ◽  
Platelet Function ◽  
Calcium Release ◽  
Intravenous Immunoglobulins ◽  
Flow Chamber ◽  
Platelet Destruction ◽  
Immunoglobulin Preparations ◽  
Immunoglobulin Preparation ◽  
Polyvalent Immunoglobulin

Platelets play an important role in the development and progression of respiratory distress. Functional platelets are known to seal inflammatory endothelial gaps and loss of platelet function has been shown to result in loss of integrity of pulmonary vessels. This leads to fluid accumulation in the pulmonary interstitium, eventually resulting in respiratory distress. Streptococcus pneumoniae is one of the major pathogens causing community-acquired pneumonia. Previously, we have shown that its major toxin pneumolysin forms pores in platelet membranes and renders them non-functional. In vitro, this process was inhibited by polyvalent intravenous immunoglobulins (IVIG). In this study, we compared the efficacy of a standard intravenous immunoglobulin preparation (IVIG, 98% IgG; Privigen, CSL Behring, USA) and an IgM/IgA-enriched immunoglobulin preparation (21% IgA, 23% IgM, 56% IgG; trimodulin, Biotest AG, Germany) to inhibit pneumolysin-induced platelet destruction. Platelet destruction and functionality were assessed by flow cytometry, intracellular calcium release, aggregometry, platelet viability, transwell, and flow chamber assays. Overall, both immunoglobulin preparations efficiently inhibited pneumolysin-induced platelet destruction. The capacity to antagonize pneumolysin mainly depended on the final IgG content. As both polyvalent immunoglobulin preparations efficiently prevent pneumolysin-induced platelet destruction and maintain platelet function in vitro, they represent promising candidates for clinical studies on supportive treatment of pneumococcal pneumonia to reduce progression of respiratory distress.

scholarly journals High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients

Blood ◽  
1984 ◽  
Vol 64 (4) ◽  
pp. 937-940 ◽  
Author(s):  
CA Schiffer ◽  
DE Hogge ◽  
J Aisner ◽  
JP Dutcher ◽  
EJ Lee ◽  
...  
Keyword(s):  
Platelet Transfusion ◽  
Reticuloendothelial System ◽  
Final Concentration ◽  
Red Cross ◽  
High Dose ◽  
Platelet Concentrates ◽  
Intravenous Gammaglobulin ◽  
G Prior ◽  
Polyvalent Immunoglobulin ◽  
Lymphocytotoxic Antibody

Abstract High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (ITP), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor platelet transfusion using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously X five days (four patients) or 0.6 g/kg/d X five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrates incubated for 30 minutes at 37 degrees C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely expensive treatment, cannot be recommended for alloimmunized adults with leukemia.

Cytomegalovirus Prophylaxis With Intravenous Polyvalent Immunoglobulin in High-Risk Renal Transplant Recipients

2006 ◽  
Vol 38 (7) ◽  
pp. 2324-2326 ◽  
Author(s):  
F. Leroy ◽  
A. Sechet ◽  
R. Abou Ayache ◽  
A. Thierry ◽  
S. Belmouaz ◽  
...  
Keyword(s):  
High Risk ◽  
Renal Transplant ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Polyvalent Immunoglobulin

scholarly journals High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients

Blood ◽  
1984 ◽  
Vol 64 (4) ◽  
pp. 937-940 ◽  
Author(s):  
CA Schiffer ◽  
DE Hogge ◽  
J Aisner ◽  
JP Dutcher ◽  
EJ Lee ◽  
...  
Keyword(s):  
Platelet Transfusion ◽  
Reticuloendothelial System ◽  
Final Concentration ◽  
Red Cross ◽  
High Dose ◽  
Platelet Concentrates ◽  
Intravenous Gammaglobulin ◽  
G Prior ◽  
Polyvalent Immunoglobulin ◽  
Lymphocytotoxic Antibody

High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (ITP), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor platelet transfusion using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously X five days (four patients) or 0.6 g/kg/d X five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrates incubated for 30 minutes at 37 degrees C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely expensive treatment, cannot be recommended for alloimmunized adults with leukemia.

Sign in / Sign up

Export Citation Format

Share Document